Gold prices just lower; monthly gains on track
Director William W. Brooke purchased 50,000 shares of MAXCYTE, INC. (NASDAQ:MXCT) common stock on August 13, 2025, at a price of $1.29 per share. The total value of the purchase was $64,500. Following the transaction, Brooke directly owns 150,879 shares of the company. The purchase comes as the stock trades near its 52-week low of $1.26, having declined over 66% in the past six months. While the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 12.39, InvestingPro analysis suggests the stock is currently in oversold territory and trading below its Fair Value. For deeper insights into insider trading patterns and 12 additional key metrics, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, MaxCyte Inc. reported its second-quarter 2025 earnings, missing revenue forecasts with $8.5 million, which fell short of the projected $9.63 million. The company’s earnings per share (EPS) stood at -$0.12, slightly below the expected -$0.10. This earnings miss contributed to a downgraded outlook, with MaxCyte reducing its 2025 revenue guidance by $5 million, indicating a potential 14% reduction in business. Analysts have responded to these developments, with BTIG downgrading MaxCyte from Buy to Neutral, citing ongoing funding challenges for its cell and gene therapy customers. William Blair also downgraded the company from Outperform to Market Perform, highlighting the disappointing performance and reduced guidance. The revised guidance suggests a core organic revenue decline of 6%-16% for the year, including an approximately 20% drop in the second half. These updates reflect significant challenges faced by MaxCyte in maintaining its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.